行情

LQDA

LQDA

Liquidia Technologies
NASDAQ

实时行情|Nasdaq Last Sale

5.99
-0.53
-8.13%
已收盘, 16:00 01/27 EST
开盘
6.00
昨收
6.52
最高
6.21
最低
5.90
成交量
16.02万
成交额
--
52周最高
20.05
52周最低
2.650
市值
9,053.77万
市盈率(TTM)
-2.3854
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LQDA 新闻

  • 瑞士国家旅游局:愿与中国旅游业者共克时艰
  • 中国新闻网.25分钟前
  • 日本政府提名支持宽松的经济学家安达诚司为央行执委
  • 新浪财经.31分钟前
  • 苹果上半年拟生产8000万部iPhone 全年增产10%
  • IT之家.33分钟前
  • 巴西反垄断监管机构批准波音与巴航工业合作计划
  • 新华网.54分钟前

更多

所属板块

制药
-0.42%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

LQDA 简况

Liquidia Technologies, Inc. is a clinical biopharmaceutical company, which is focused on the developing and commercialization of human therapeutics using its PRINT technology. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The Company is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
展开

Webull提供Liquidia Technologies Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。